Numerous studies have indicated that markedly increased levels of LGALS3BP in serum or tumor tissues have been linked to adverse clinical outcomes in various malignancies, such as neuroblastoma, glioblastoma, breast cancer, and endometrial cancer [28–32]. The gene discussed is LGALS3BP; the disease is neuroblastoma.